| A transcriptional corepressor of Stat1 with an essential LXXLL signature motif B Liu, M Gross, J ten Hoeve, K Shuai Proceedings of the National Academy of Sciences 98 (6), 3203-3207, 2001 | 274 | 2001 |
| Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years D Bahn, AL de Castro Abreu, IS Gill, AJ Hung, P Silverman, ME Gross, ... European urology 62 (1), 55-63, 2012 | 257 | 2012 |
| Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer EY Yu, G Wilding, E Posadas, M Gross, S Culine, C Massard, MJ Morris, ... Clinical Cancer Research 15 (23), 7421-7428, 2009 | 248 | 2009 |
| Activity of second‐line chemotherapy in docetaxel‐refractory hormone‐refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone JE Rosenberg, VK Weinberg, WK Kelly, D Michaelson, MH Hussain, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2007 | 229 | 2007 |
| Distinct effects of PIAS proteins on androgen-mediated gene activation in prostate cancer cells M Gross, B Liu, J Tan, FS French, M Carey, K Shuai Oncogene 20 (29), 3880-3887, 2001 | 208 | 2001 |
| 3-Dimensional elastic registration system of prostate biopsy location by real-time 3-dimensional transrectal ultrasound guidance with magnetic resonance/transrectal ultrasound … O Ukimura, MM Desai, S Palmer, S Valencerina, M Gross, AL Abreu, ... The Journal of urology 187 (3), 1080-1086, 2012 | 189 | 2012 |
| Rapid phenotypic and genomic change in response to therapeutic pressure in prostate cancer inferred by high content analysis of single circulating tumor cells AE Dago, A Stepansky, A Carlsson, M Luttgen, J Kendall, T Baslan, ... PloS one 9 (8), e101777, 2014 | 168 | 2014 |
| Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer H Jadvar, B Desai, L Ji, PS Conti, TB Dorff, SG Groshen, ME Gross, ... Clinical nuclear medicine 37 (7), 637-643, 2012 | 156 | 2012 |
| Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer Y Jiang, JF Palma, DB Agus, Y Wang, ME Gross Clinical chemistry 56 (9), 1492-1495, 2010 | 152 | 2010 |
| Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial JK Dawson, TB Dorff, E Todd Schroeder, CJ Lane, ME Gross, ... BMC cancer 18, 1-15, 2018 | 122 | 2018 |
| Cellular growth response to epidermal growth factor in colon carcinoma cells with an amplified epidermal growth factor receptor derived from a familial adenomatous polyposis … ME Gross, MA Zorbas, YJ Danels, R Garcia, GE Gallick, M Olive, ... Cancer research 51 (5), 1452-1459, 1991 | 116 | 1991 |
| PIASy-mediated repression of the androgen receptor is independent of sumoylation M Gross, R Yang, I Top, C Gasper, K Shuai Oncogene 23 (17), 3059-3066, 2004 | 112 | 2004 |
| Targeting the HER-kinase axis in cancer ME Gross, RL Shazer, DB Agus Seminars in oncology 31, 9-20, 2004 | 112 | 2004 |
| A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer M Gross, C Higano, A Pantuck, O Castellanos, E Green, K Nguyen, ... BMC cancer 7, 1-6, 2007 | 97 | 2007 |
| Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer YY Evan, C Massard, ME Gross, MA Carducci, S Culine, G Hudes, ... Urology 77 (5), 1166-1171, 2011 | 96 | 2011 |
| Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design KW Beekman, AD Colevas, K Cooney, R DiPaola, RL Dunn, M Gross, ... Clinical genitourinary cancer 4 (4), 299-302, 2006 | 96 | 2006 |
| Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene CI Müller, CW Miller, WK Hofmann, ME Gross, CS Walsh, N Kawamata, ... Leukemia research 31 (1), 27-32, 2007 | 93 | 2007 |
| Anterior gradient 2 (AGR2): blood‐based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype K Kani, PD Malihi, Y Jiang, H Wang, Y Wang, DL Ruderman, DB Agus, ... The Prostate 73 (3), 306-315, 2013 | 84 | 2013 |
| Intolerance of uncertainty, cognitive complaints, and cancer‐related distress in prostate cancer survivors SA Eisenberg, K Kurita, M Taylor‐Ford, DB Agus, ME Gross, ... Psycho‐Oncology 24 (2), 228-235, 2015 | 83 | 2015 |
| Trans-rectal ultrasound visibility of prostate lesions identified by magnetic resonance imaging increases accuracy of image-fusion targeted biopsies O Ukimura, A Marien, S Palmer, A Villers, M Aron, AL de Castro Abreu, ... World journal of urology 33, 1669-1676, 2015 | 82 | 2015 |